ZURICH, Nov 28 (Reuters) - Actelion Chief Executive
Jean-Paul Clozel's desire to keep Europe's biggest biotech
company independent after building it from scratch, means
Johnson & Johnson will have to pay a steep premium if a
takeover is to succeed.
Read more
No comments:
Post a Comment